First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

A Phase 1 Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX9930 in Healthy Subjects and in Subjects With Paroxysmal Nocturnal Hemoglobinuria

This is a 3-part Phase 1 dose-ranging study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single (Part 1) and multiple (Part 2) ascending doses of BCX9930 in healthy subjects and in subjects with paroxysmal nocturnal hemoglobinuria (PNH; Part 3). Pharmacokinetics is an analysis of how the body handles the study drug BCX9930 and pharmacodynamics is an analysis of the activity that the study drug BCX9930 may have in the body.

Study Overview

• Status: Completed
• Conditions: Paroxysmal Nocturnal Hemoglobinuria
• Intervention / Treatment: Drug: BCX9930; Drug: Placebo

Detailed Description

Up to 6 sequential ascending dose cohorts are planned to be dosed in a sequential manner in Part 1 of the study. Eight subjects will be treated with a single dose of the study drug per dose cohort (6 subjects per cohort will receive BCX9930 and 2 subjects per cohort will receive matching placebo). Escalation to the next higher dose level will occur only after completion of a review of clinical safety and pharmacokinetics by the Sponsor and PI.

Up to 7 ascending, multiple dose cohorts will be enrolled in a sequential manner in Part 2 of the study. In Cohorts 1 through 3, twelve subjects will be treated with either a 7-day or 14-day course of study drug (10 subjects per cohort will receive BCX9930 and 2 subjects per cohort will receive matching placebo) administered orally. In Cohorts 4 through 7, twelve subjects will be treated with a 3-day course of study drug (10 subjects per cohort will receive BCX9930 and 2 subjects per cohort will receive matching placebo) administered orally. The daily dose may be split into 2 times daily (BID) or 3 times daily (TID) dosing for the multiple ascending dose part as needed. Escalation to the next higher dose level in Part 2 will occur only after completion of a review of clinical safety and pharmacokinetics by the Sponsor and PI.

Part 3 of the study consists of up to 2 sequential ascending multiple dose cohorts of up to 8 subjects; each cohort may enroll up to 4 subjects with PNH who are naïve to both eculizumab and ravulizumab and up to 4 subjects with PNH who are currently being treated with either eculizumab or ravulizumab. In each cohort, subjects will receive one daily dose of BCX9930 on Days 1 to 14 and a higher daily dose on Days 15 to 28. Cohort 2 will start after independent data monitoring committee (DMC) review of Cohort 1 data and communication of their evaluation to Part 3 investigators. In South Africa, subjects that have clinical benefit from BCX9930 will be allowed to continue dosing for up to 48 weeks.

• Study Type: Interventional
• Enrollment (Actual): 168
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Austria
  • Vienna, Austria
    • Study Site
• South Africa
  • Bloemfontein, South Africa
    • Study Site
  • Pretoria, South Africa
    • Study Site
• United Kingdom
  • London, United Kingdom
    • Study Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria (Parts 1, 2, and 3):

• Able to provide written informed consent
• Acceptable birth control measures for male subjects and women of childbearing potential
• Is expected to adequately comply with required study procedures and restrictions

Key Inclusion Criteria (Parts 1 and 2):

• Body mass index (BMI) of 18.0 to 32.0 kg/m2.
• Males and non-pregnant, non-lactating females age 18 to 55 years.
• Part 2: Must have recent vaccination against Neisseria meningitidis and must be negative for colonisation by Neisseria meningitidis

Key Inclusion Criteria (Part 3 only):

• Male or non-pregnant, non-lactating female subjects ≥ 18 years old
• Have been diagnosed with PNH and have laboratory values indicative of active PNH
• Subjects naïve to both eculizumab and ravulizumab treatment, who have no access to, or are considered unsuitable for proven effective alternative options as per the local standard of care OR subjects currently receiving treatment with eculizumab or ravulizumab have been on a stable dose of eculizumab or ravulizumab for 6 months
• Must have recent vaccination against Neisseria meningitidis

Key Exclusion Criteria (Parts 1 and 2):

• Clinically significant medical history, current medical or psychiatric condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject.
• Clinically significant ECG finding or laboratory/urinalysis abnormality
• Use of prescription or over the counter medication within 14 days of dosing
• Participation in any other investigational drug study within 90 days of screening
• Recent or current history of alcohol or drug abuse within the last 12 months
• Current smokers and those who have smoked within the last 12 months
• Positive serology for HIV or active infection with HBV or HCV
• Pregnant or nursing
• Donation or loss of greater than 400 mL of blood within 3 months
• History of severe hypersensitivity to any drug or Neisseria meningitidis vaccines (Part 2)
• Subject has recently received a live attenuated vaccine within 30 days of dosing or another type of vaccine within 14 days of Day 1

Key Exclusion Criteria (Part 3):

• Apart from a diagnosis of PNH, any clinically significant medical or psychiatric condition or medical history, other than those associated with PNH disease, that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study or participation would increase the risk for that subject
• Active bacterial infection
• Hereditary complement deficiency
• History of hematopoietic stem cell /marrow transplantation
• Current participation in any other investigational drug study or participation in an investigational drug study within 30 days of the screening visit
• History of meningococcal disease
• Positive drugs of abuse screen at screening visit
• Pregnant, planning to become pregnant, or having been pregnant within 90 days of Day 1, or lactating
• History of severe hypersensitivity to any drug

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BCX9930; Parts 1, 2 and 3	Drug: BCX9930; BCX9930 capsules for oral administration
Placebo Comparator: Placebo; Parts 1 and 2 only	Drug: Placebo; placebo to match BCX9930 capsules for oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of graded treatment-emergent adverse events	Part 1: Day 16
Incidence of graded treatment-emergent adverse events	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Incidence of graded treatment-emergent adverse events	Part 3:Day 44 or Week 50 (South Africa only)
Incidence of graded laboratory chemistry abnormalities	Part 1: Day 16
Incidence of graded laboratory chemistry abnormalities	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Incidence of graded laboratory chemistry abnormalities	Part 3:Day 44 or Week 50 (South Africa only)
Incidence of graded urinalysis abnormalities	Part 1: Day 16
Incidence of graded urinalysis abnormalities	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Incidence of graded urinalysis abnormalities	Part 3: Day 44 or Week 50 (South Africa only)
Incidence of graded coagulation abnormalities	Part 1: Day 16
Incidence of graded coagulation abnormalities	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Incidence of graded coagulation abnormalities	Part 3: Day 44 or Week 50 (South Africa only)
Incidence of graded hematology abnormalities	Part 1: Day 16
Incidence of graded hematology abnormalities	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Incidence of graded hematology abnormalities	Part 3: Day 44 or Week 50 (South Africa only)
Change from baseline in blood pressure	Part 1: Day 16
Change from baseline in blood pressure	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Change from baseline in blood pressure	Part 3: Day 44 or Week 50 (South Africa only)
Change from baseline in temperature	Part 1: Day 16
Change from baseline in temperature	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Change from baseline in temperature	Part 3: Day 44 or Week 50 (South Africa only)
Change from baseline in heart rate	Part 1: Day 16
Change from baseline in heart rate	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Change from baseline in heart rate	Part 3: Day 44 or Week 50 (South Africa only)
Change from baseline in respiratory rate	Part 3: Day 44 or Week 50 (South Africa only)
Change in Electrocardiogram (PR interval)	Part 1: Day 16
Change in Electrocardiogram (PR interval)	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Change in Electrocardiogram (PR interval)	Part 3: Day 44 or Week 50 (South Africa only)
Change in Electrocardiogram (QRS interval)	Part 1: Day 16
Change in Electrocardiogram (QRS interval)	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Change in Electrocardiogram (QRS interval)	Part 3: Day 44 or Week 50 (South Africa only)
Change in Electrocardiogram (RR interval)	Part 1: Day 16
Change in Electrocardiogram (RR interval)	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Change in Electrocardiogram (RR interval)	Part 3:Day 44 or Week 50 (South Africa only)
Change in Electrocardiogram (QT interval)	Part 1: Day 16
Change in Electrocardiogram (QT interval)	Part 2: Day 23 (cohorts with 3 and 7 day dosing duration) or Day 31 (cohorts with 14 day dosing duration)
Change in Electrocardiogram (QT interval)	Part 3:Day 44 or Week 50 (South Africa only)

Secondary Outcome Measures

Outcome Measure	Time Frame
Plasma BCX9930 Cmax	plasma PK parameters are based on blood sampling through Day 4 for Part 1; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3
Plasma BCX9930 Tmax	plasma PK parameters are based on blood sampling through Day 4 for Part 1; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3
Plasma BCX9930 AUCinf	plasma PK parameters are based on blood sampling through Day 4 for Part 1
Plasma BCX9930 t1/2	plasma PK parameters are based on blood sampling through Day 4 for Part 1; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3
Plasma BCX9930 AUCtau	plasma PK parameters are based on blood sampling through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and through Day 28 for Part 3
Serum AP complement activity	Part 1:through Study Day 4; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and Part 3 through Day 28 or Week 48 (South Africa only)
Plasma Factor Bb	Part 1:through Study Day 4; through Day 6, 14 or 18 for Part 2 (Day depends on dosing duration); and Part 3 through Day 28 or Week 48 (South Africa only)
Number of blood transfusions	Part 3:baseline through Day 28 or Week 50 (South Africa only)
Lactate dehydrogenase	Part 3: absolute and change from baseline through Day 28 or Week 50 (South Africa only)
Hemoglobin	Part 3: absolute and change from baseline through Day 28 or Week 50 (South Africa only)
Absolute reticulocyte count	Part 3: values and change from baseline through Day 28 or Week 50 (South Africa only)
Haptoglobin	Part 3: absolute and change from baseline through Day 28 or Week 50 (South Africa only)

Collaborators and Investigators

• Sponsor: BioCryst Pharmaceuticals
• Investigators: Principal Investigator: Antionio Risitano, University of Naples

Study record dates

Study Major Dates

• Study Start (Actual): March 3, 2020
• Primary Completion (Actual): November 11, 2020
• Study Completion (Actual): January 25, 2021

Study Registration Dates

• First Submitted: March 23, 2020
• First Submitted That Met QC Criteria: March 30, 2020
• First Posted (Actual): April 1, 2020

Study Record Updates

• Last Update Posted (Actual): February 17, 2022
• Last Update Submitted That Met QC Criteria: February 15, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: first-in-human; Paroxysmal Nocturnal Hemoglobinuria; proof-of-concept; complement inhibitor; BioCryst; Factor D; alternative pathway inhibitor
• Additional Relevant MeSH Terms: Urologic Diseases; Urological Manifestations; Bone Marrow Diseases; Hematologic Diseases; Urination Disorders; Anemia; Proteinuria; Anemia, Hemolytic; Myelodysplastic Syndromes; Hemoglobinuria; Hemoglobinuria, Paroxysmal
• Other Study ID Numbers: BCX9930-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No